SPRINT to Stop Alzheimer’s by 2020

Spending Reductions through Innovations in Therapies (SPRINT)

GOAL: Stop Alzheimer’s Disease by 2020

SPRINT reforms accelerate the therapeutic pipeline through new processes & tools:
- Open innovation platforms
- Collaborative problem-solving
- Public-private partnerships
- Targeted outcome-oriented investments
- Enhanced incentives for private investment
- Increased standardization & data disclosure

Today’s Therapeutic Pipeline

Basic Research: Acute funding challenges, especially for NIA
Translational Research: Scientific challenges, little investment or focus
Early Clinical Development: Time-consuming & costly process, declining investments
Late Clinical Development: Restrictive study endpoints & metrics, high cost, lengthy process
FDA Review: Risk-averse and unpredictable decision making, lengthy review cycles, complex regulations
Clinical Use & Payment: Inadequate incentives, unclear reimbursement process, clinician discomfort with Alzheimer’s, poor care coordination

Valley of Death

The SPRINT Difference

Basic Research: Increase targets with enhanced resources for Alzheimer’s research
Translational Research: Invest in translational science and protocols to de-risk molecular candidates
Early Clinical Development: Expedite breakthroughs via accountable, goal-oriented, milestone-driven public-private investments
Late Clinical Development: Reduce cost and time to market through early & increased dialogue with FDA, biomarker guidance, patient registries
FDA Review: Accelerate process for therapies through expedited, innovative and predictable reviews; reduce regulatory burdens; increase patient input: disease severity
Clinical Use & Payment: Provide market incentives & appropriate reimbursement; educate clinicians on detection, therapies, and care planning

US Against Alzheimer’s
we can stop it by 2020.

v12, February 4, 2012
ALZHEIMER’S REQUIRES AN INTEGRATED GLOBAL SOLUTION

WORLD DEMENTIA COUNCIL AND NAPA ADVISORY COUNCIL

- Science and Government Funding
- Industry Biopharma, Finance, Technology
- Regulation
- Payers
- Politics and Policy
WE'RE WORKING ON EACH PIECE TO STOP ALZHEIMER'S

WORLD DEMENTIA COUNCIL AND NAPA ADVISORY COUNCIL

LEAD and ResearchersAgainstAlzheimer's

CEOi and USAgainstAlzheimer's

CEOi and 21stCenturyBrainTrust

AfricanAmericansAgainstAlzheimer's, USAgainstAlzheimer's PAC, and LEAD